Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

被引：0
|
作者：
机构：
[1] Lancet Oncol, 125 London Wall, London EC2Y 5AS, England
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 04期
关键词：
D O I：
10.1016/S1470-2045(23)00111-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E145 / E145
页数：1
相关论文
共 50 条
  • [21] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
  • [22] Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study
    Dummer, Reinhard
    Levesque, Mitchell
    Bellini, Elisa
    Chen, Marissa
    Hu, Youyou
    Wong, Tiffany
    Stassen, Katja
    Duhard, Pauline
    Yan, Yibing
    Tawbi, Hussein A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
    Hochhaus, Andreas
    Baccarani, Michele
    Giles, Francis J.
    Le Coutre, Philipp D.
    Mueller, Martin C.
    Reiter, Andreas
    Santanastasio, Helene
    Leung, Mimi
    Novick, Steven
    Kantarjian, Hagop M.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (11) : 2047 - 2060
  • [24] Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
    Andreas Hochhaus
    Michele Baccarani
    Francis J. Giles
    Philipp D. le Coutre
    Martin C. Müller
    Andreas Reiter
    Helene Santanastasio
    Mimi Leung
    Steven Novick
    Hagop M. Kantarjian
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 2047 - 2060
  • [25] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
  • [26] Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
    Di Giacomo, Anna Maria
    Ascierto, Paolo A.
    Pilla, Lorenzo
    Santinami, Mario
    Ferrucci, Pier Francesco
    Giannarelli, Diana
    Marasco, Antonella
    Rivoltini, Licia
    Simeone, Ester
    Nicoletti, Stefania V. L.
    Fonsatti, Ester
    Annesi, Diego
    Queirolo, Paola
    Testori, Alessandro
    Ridolfi, Ruggero
    Parmiani, Giorgio
    Maio, Michele
    LANCET ONCOLOGY, 2012, 13 (09): : 879 - 886
  • [27] Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
    Larkin, James
    Del Vecchio, Michele
    Ascierto, Paolo A.
    Krajsova, Ivana
    Schachter, Jacob
    Neyns, Bart
    Espinosa, Enrique
    Garbe, Claus
    Sileni, Vanna Chiarion
    Gogas, Helen
    Miller, Wilson H., Jr.
    Mandala, Mario
    Hospers, Geke A. P.
    Arance, Ana
    Queirolo, Paola
    Hauschild, Axel
    Brown, Michael P.
    Mitchell, Lada
    Veronese, Luisa
    Blank, Christian U.
    LANCET ONCOLOGY, 2014, 15 (04): : 436 - 444
  • [28] Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
    Si, Lu
    Zou, Zhengyun
    Zhang, Weizhen
    Fang, Meiyu
    Zhang, Xiaoshi
    Luo, Zhiguo
    Chen, Jing
    Huang, Gang
    Zhang, Peng
    Cheng, Ying
    Liu, Jiwei
    Liu, Jiyan
    Zhang, Junping
    Wu, Di
    Chen, Yu
    Ma, Xiaobiao
    Wei, Xiaoting
    Sun, Peng
    Jia, Zhongwei
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study
    Negrier, Claude
    Mahlangu, Johnny
    Lehle, Michaela
    Chowdary, Pratima
    Catalani, Olivier
    Bernardi, Ronald J.
    Jimenez-Yuste, Victor
    Beckermann, Benjamin M.
    Schmitt, Christophe
    Ventriglia, Giuliana
    Windyga, Jerzy
    d'Oiron, Roseline
    Moorehead, Paul
    Koparkar, Sunita
    Teodoro, Vanda
    Shapiro, Amy D.
    Oldenburg, Johannes
    Hermans, Cedric
    LANCET HAEMATOLOGY, 2023, 10 (03): : e168 - e177
  • [30] A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma and central nervous system (CNS) metastases (mets).
    Queirolo, Paola
    de la Cruz Merino, Luis
    Abajo Guijarro, Ana Maria
    Tawbi, Hussein Abdul-Hassan
    Dummer, Reinhard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345